223 related articles for article (PubMed ID: 21630667)
1. Initial efforts toward the optimization of arylomycins for antibiotic activity.
Roberts TC; Schallenberger MA; Liu J; Smith PA; Romesberg FE
J Med Chem; 2011 Jul; 54(14):4954-63. PubMed ID: 21630667
[TBL] [Abstract][Full Text] [Related]
2. Broad-spectrum antibiotic activity of the arylomycin natural products is masked by natural target mutations.
Smith PA; Roberts TC; Romesberg FE
Chem Biol; 2010 Nov; 17(11):1223-31. PubMed ID: 21095572
[TBL] [Abstract][Full Text] [Related]
3. Efforts toward broadening the spectrum of arylomycin antibiotic activity.
Liu J; Smith PA; Steed DB; Romesberg F
Bioorg Med Chem Lett; 2013 Oct; 23(20):5654-9. PubMed ID: 24012184
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action of the arylomycin antibiotics and effects of signal peptidase I inhibition.
Smith PA; Romesberg FE
Antimicrob Agents Chemother; 2012 Oct; 56(10):5054-60. PubMed ID: 22802255
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel cyclic lipopeptides from a positional scanning combinatorial library with enhanced antibacterial and antibiofilm activities.
Bionda N; Fleeman RM; de la Fuente-Núñez C; Rodriguez MC; Reffuveille F; Shaw LN; Pastar I; Davis SC; Hancock REW; Cudic P
Eur J Med Chem; 2016 Jan; 108():354-363. PubMed ID: 26703794
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of arylomycin natural-product antibiotics against Staphylococcus epidermidis and other coagulase-negative staphylococci.
Smith PA; Powers ME; Roberts TC; Romesberg FE
Antimicrob Agents Chemother; 2011 Mar; 55(3):1130-4. PubMed ID: 21189343
[TBL] [Abstract][Full Text] [Related]
7. Optimized arylomycins are a new class of Gram-negative antibiotics.
Smith PA; Koehler MFT; Girgis HS; Yan D; Chen Y; Chen Y; Crawford JJ; Durk MR; Higuchi RI; Kang J; Murray J; Paraselli P; Park S; Phung W; Quinn JG; Roberts TC; Rougé L; Schwarz JB; Skippington E; Wai J; Xu M; Yu Z; Zhang H; Tan MW; Heise CE
Nature; 2018 Sep; 561(7722):189-194. PubMed ID: 30209367
[TBL] [Abstract][Full Text] [Related]
8. Total Synthesis of Laspartomycin C and Characterization of Its Antibacterial Mechanism of Action.
Kleijn LH; Oppedijk SF; 't Hart P; van Harten RM; Martin-Visscher LA; Kemmink J; Breukink E; Martin NI
J Med Chem; 2016 Apr; 59(7):3569-74. PubMed ID: 26967152
[TBL] [Abstract][Full Text] [Related]
9. Discovery, Synthesis, and Optimization of Peptide-Based Antibiotics.
Hanna CC; Hermant YO; Harris PWR; Brimble MA
Acc Chem Res; 2021 Apr; 54(8):1878-1890. PubMed ID: 33750106
[TBL] [Abstract][Full Text] [Related]
10. Semisynthetic approaches to laspartomycin analogues.
Curran WV; Leese RA; Jarolmen H; Borders DB; Dugourd D; Chen Y; Cameron DR
J Nat Prod; 2007 Mar; 70(3):447-50. PubMed ID: 17323996
[TBL] [Abstract][Full Text] [Related]
11. Antibacterial sulfonimidamide-based oligopeptides as type I signal peptidase inhibitors: Synthesis and biological evaluation.
Benediktsdottir A; Lu L; Cao S; Zamaratski E; Karlén A; Mowbray SL; Hughes D; Sandström A
Eur J Med Chem; 2021 Nov; 224():113699. PubMed ID: 34352713
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of octapeptin C4 and biological profiling against NDM-1 and polymyxin-resistant bacteria.
Becker B; Butler MS; Hansford KA; Gallardo-Godoy A; Elliott AG; Huang JX; Edwards DJ; Blaskovich MAT; Cooper MA
Bioorg Med Chem Lett; 2017 Jun; 27(11):2407-2409. PubMed ID: 28454673
[TBL] [Abstract][Full Text] [Related]
13. Type I signal peptidase and protein secretion in Staphylococcus aureus.
Schallenberger MA; Niessen S; Shao C; Fowler BJ; Romesberg FE
J Bacteriol; 2012 May; 194(10):2677-86. PubMed ID: 22447899
[TBL] [Abstract][Full Text] [Related]
14. Linear Analogues of the Lipopeptide Battacin With Potent In Vitro Activity Against S. aureus.
Glossop HD; Pearl E; De Zoysa GH; Sarojini V
Adv Protein Chem Struct Biol; 2018; 112():385-394. PubMed ID: 29680242
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship of potent antimicrobial peptide analogs of Ixosin-B amide.
Wu YS; Liao ZJ; Wang KS; Lung FD
Bioorg Med Chem Lett; 2013 May; 23(10):2929-32. PubMed ID: 23570790
[TBL] [Abstract][Full Text] [Related]
16. Novel antibiotics: C-2 symmetrical macrocycles inhibiting Holliday junction DNA binding by E. coli RuvC.
Pan PS; Curtis FA; Carroll CL; Medina I; Liotta LA; Sharples GJ; McAlpine SR
Bioorg Med Chem; 2006 Jul; 14(14):4731-9. PubMed ID: 16581254
[TBL] [Abstract][Full Text] [Related]
17. Initial Analysis of the Arylomycin D Antibiotics.
Tan YX; Peters DS; Walsh SI; Holcomb M; Santos-Martins D; Forli S; Romesberg FE
J Nat Prod; 2020 Jul; 83(7):2112-2121. PubMed ID: 32614583
[TBL] [Abstract][Full Text] [Related]
18. Novel Cyclic Lipopeptide Antibiotics: Effects of Acyl Chain Length and Position.
Jensen SK; Thomsen TT; Oddo A; Franzyk H; Løbner-Olesen A; Hansen PR
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823798
[TBL] [Abstract][Full Text] [Related]
19. A putative cro-like repressor contributes to arylomycin resistance in Staphylococcus aureus.
Craney A; Romesberg FE
Antimicrob Agents Chemother; 2015; 59(6):3066-74. PubMed ID: 25753642
[TBL] [Abstract][Full Text] [Related]
20. Broadening the spectrum of β-lactam antibiotics through inhibition of signal peptidase type I.
Therien AG; Huber JL; Wilson KE; Beaulieu P; Caron A; Claveau D; Deschamps K; Donald RG; Galgoci AM; Gallant M; Gu X; Kevin NJ; Lafleur J; Leavitt PS; Lebeau-Jacob C; Lee SS; Lin MM; Michels AA; Ogawa AM; Painter RE; Parish CA; Park YW; Benton-Perdomo L; Petcu M; Phillips JW; Powles MA; Skorey KI; Tam J; Tan CM; Young K; Wong S; Waddell ST; Miesel L
Antimicrob Agents Chemother; 2012 Sep; 56(9):4662-70. PubMed ID: 22710113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
